title: Enhancement of the thermal response of murine tumour and normal tissues by a streptococcal preparation, OK-432 (Picibanil).
abstract: We have studied the effect of a streptococcal preparation, OK-432, given alone or in combination with hyperthermia on murine tumour and normal tissues. The experimental tumour was a spontaneous non-immunogenic fibrosarcoma FSa-II transplanted in the foot of C3Hf/Sed mice. Local hyperthermia was achieved by immersing the mouse foot into a constant temperature water bath (42-45 degrees C) for various lengths of time. Tumour response was studied by analysing the tumour growth (TG) time. Various doses of OK-432 (1-5 KE/mouse) were injected locally into the tumour. Local administration of OK-432 alone (without hyperthermia) had no effect on the TG time. Thermal enhancement ratio (TER) for combined treatment was independent of drug dose greater than or equal to 2 KE, and the mean TER was 1.48 +/- 0.27 (95% CL). The TER was greater for 6 mm tumours than for 4 mm tumours, and it was greatest if the time interval between hyperthermia and drug administration was 3 h or less. There was no effect if the drug was administrated 4 days before hyperthermia, but its application 9 days prior to hyperthermia caused a slight prolongation of the TG time of non-heated tumours, and a reduction in the TG time of heated tumours. Normal-tissue response was studied by scoring the peak foot reaction and RD50 (the treatment time to induce a specified response in one-half of the treated animals). The effect of OK-432 on the thermal response of the foot was also studied at various temperatures. The mean TER was 1.11 +/- 0.07. Local administration of OK-432 failed to modify significantly the kinetics of thermotolerance. Present experiments demonstrated that OK-432 after local administration enhanced the thermal response of murine tumour and normal tissues. This enhancement was greater for the tumour than for the normal tissue, resulting in a favourable differential effect between normal and malignant tissues (the average therapeutic gain was 1.33 +/- 0.19).
authors.affiliation: Department of Radiation Medicine, University of Kentucky, Chandler Medical Center, Lexington 40536.
authors.forename: M
authors.initials: M
authors.lastname: Urano
authors.forename: M
authors.initials: M
authors.lastname: Taradi
authors.forename: S K
authors.initials: SK
authors.lastname: Taradi
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D006358:Hot Temperature / Q000009:adverse effects / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D010844:Picibanil / Q000008:administration & dosage*; D012513:Sarcoma, Experimental / Q000276:immunology / Q000628:therapy*; D013696:Temperature; D013997:Time Factors
chemical_list: D010844:Picibanil